Lactobacillus casei Shirota Supplementation Does Not Restore Gut Microbiota Composition and Gut Barrier in Metabolic Syndrome: A Randomized Pilot Study.
Metabolic syndrome is associated with disturbances in gut microbiota composition. We aimed to investigate the effect of Lactobacillus casei Shirota (LcS) on gut microbiota composition, gut barrier integrity, intestinal inflammation and serum bile acid profile in metabolic syndrome. In a single-centre, prospective, randomised controlled pilot study, 28 subjects with metabolic syndrome received either LcS for 12 weeks (n = 13) or no LcS (n = 15). Data were compared to healthy controls (n = 16). Gut microbiota composition was characterised from stool using 454 pyrosequencing of 16S rRNA genes. Serum bile acids were quantified by tandem mass spectrometry. Zonulin and calprotectin were measured in serum and stool by ELISA. Bacteroidetes/Firmicutes ratio was significantly higher in healthy controls compared to metabolic syndrome but was not influenced by LcS. LcS supplementation led to enrichment of Parabacteroides. Zonulin and calprotectin were increased in metabolic syndrome stool samples but not influenced by LcS supplementation. Serum bile acids were similar to controls and not influenced by LcS supplementation. Metabolic syndrome is associated with a higher Bacteroidetes/Firmicutes ratio and gut barrier dysfunction but LcS was not able to change this. LcS administration was associated with subtle microbiota changes at genus level.


BACKGROUND
ClinicalTrials.gov NCT01182844.
Medical University of Graz, Division of Gastroenterology and Hepatology, Graz, Austria.
Vanessa
V
Stadlbauer
Medical University of Graz, Division of Transplantation Surgery, Graz, Austria.
Bettina
B
Leber
Medical University of Graz, Division of Gastroenterology and Hepatology, Graz, Austria.
Sandra
S
Lemesch
Centre for Medical Research, Graz, Austria.
Slave
S
Trajanoski
Medical University of Graz, Division of Endocrinology and Metabolism, Graz, Austria.
Mina
M
Bashir
Medical University of Graz, Division of Gastroenterology and Hepatology, Graz, Austria.
Angela
A
Horvath
Medical University of Graz, Division of Gastroenterology and Hepatology, Graz, Austria.
Monika
M
Tawdrous
Medical University of Graz, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Graz, Austria.
Tatjana
T
Stojakovic
Medical University of Graz, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Graz, Austria.
Günter
G
Fauler
Medical University of Graz, Division of Gastroenterology and Hepatology, Graz, Austria.
Peter
P
Fickert
Medical University of Graz, Division of Gastroenterology and Hepatology, Graz, Austria.
Christoph
C
Högenauer
Centre for Medical Research, Graz, Austria.
Ingeborg
I
Klymiuk
Medical University of Graz, Division of Transplantation Surgery, Graz, Austria.
Philipp
P
Stiegler
Medical University of Graz, Institute of Physiological Chemistry, Centre for Physiological Medicine, Graz, Austria.
Manfred
M
Lamprecht
Medical University of Graz, Division of Endocrinology and Metabolism, Graz, Austria; Centre for Biomarker Research in Medicine (CBmed), Graz, Austria.
Thomas R
TR
Pieber
Medical University of Graz, Division of Endocrinology and Metabolism, Graz, Austria.
Norbert J
NJ
Tripolt
Medical University of Graz, Division of Endocrinology and Metabolism, Graz, Austria; Centre for Biomarker Research in Medicine (CBmed), Graz, Austria.
Harald
H
Sourij
D000328:Adult; D000368:Aged; D001647:Bile Acids and Salts / Q000378:metabolism; D044822:Biodiversity; D015415:Biomarkers; D016022:Case-Control Studies; D005260:Female; D000069196:Gastrointestinal Microbiome; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism* / Q000382:microbiology*; D007780:Lacticaseibacillus casei; D008297:Male; D024821:Metabolic Syndrome / Q000378:metabolism* / Q000382:microbiology*; D008875:Middle Aged; D010865:Pilot Projects; D019936:Probiotics / Q000008:administration & dosage*
D001647:Bile Acids and Salts; D015415:Biomarkers